Wall Street analysts forecast that Cardlytics Inc (NASDAQ:CDLX) will announce earnings of ($0.40) per share for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Cardlytics’ earnings, with the lowest EPS estimate coming in at ($0.48) and the highest estimate coming in at ($0.32). The business is expected to issue its next earnings results on Thursday, August 9th.
According to Zacks, analysts expect that Cardlytics will report full-year earnings of ($1.47) per share for the current year, with EPS estimates ranging from ($1.68) to ($1.25). For the next financial year, analysts anticipate that the firm will post earnings of ($0.58) per share, with EPS estimates ranging from ($0.90) to ($0.25). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that follow Cardlytics.
Get Cardlytics alerts:Cardlytics (NASDAQ:CDLX) last announced its quarterly earnings data on Thursday, May 10th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.62) by $0.02. The business had revenue of $32.71 million during the quarter, compared to analysts’ expectations of $29.74 million.
Several brokerages have weighed in on CDLX. JPMorgan Chase & Co. began coverage on shares of Cardlytics in a research report on Tuesday, March 6th. They set an “overweight” rating and a $23.00 price target for the company. KeyCorp began coverage on shares of Cardlytics in a research report on Tuesday, March 6th. They set an “overweight” rating and a $23.00 price target for the company. Wells Fargo & Co began coverage on shares of Cardlytics in a research report on Tuesday, March 6th. They set an “outperform” rating and a $22.00 price target for the company. Bank of America began coverage on shares of Cardlytics in a research report on Tuesday, March 6th. They set a “neutral” rating and a $19.00 price target for the company. Finally, SunTrust Banks began coverage on shares of Cardlytics in a research report on Tuesday, March 6th. They set a “buy” rating and a $25.00 price target for the company. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $22.40.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. California State Teachers Retirement System purchased a new stake in Cardlytics during the 1st quarter valued at $122,000. California Public Employees Retirement System purchased a new stake in shares of Cardlytics in the 1st quarter worth about $146,000. Frontier Capital Management Co. LLC purchased a new stake in shares of Cardlytics in the 1st quarter worth about $148,000. Spark Investment Management LLC purchased a new stake in shares of Cardlytics in the 1st quarter worth about $150,000. Finally, Barclays PLC purchased a new stake in shares of Cardlytics in the 1st quarter worth about $175,000. 48.32% of the stock is owned by institutional investors and hedge funds.
CDLX traded down $0.54 during trading on Wednesday, hitting $21.28. 69,244 shares of the stock traded hands, compared to its average volume of 156,419. The stock has a market capitalization of $442.16 million and a P/E ratio of -2.65. The company has a quick ratio of 1.68, a current ratio of 1.68 and a debt-to-equity ratio of 0.81. Cardlytics has a 12-month low of $11.10 and a 12-month high of $25.71.
Cardlytics Company Profile
Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.
Get a free copy of the Zacks research report on Cardlytics (CDLX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
No comments:
Post a Comment